Work

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2020-ct165

Authors: Patricia LoRusso, Javier García-Corbacho, Fadi S. Braiteh, Anthony Gonçalves, Francesco Ricci, Hiroji Iwata, Marta Capelán, Marie Paule Sablin, Aleix Prat, Molly Catherine Hardebeck, Marta Puig, Dennis Chin-Lun Huang, Mingchi Hsu, Douglas Yee

Institutions: Yale Cancer Center, Yale University, Hospital Clínic de Barcelona, University of Nevada, Las Vegas, Comprehensive Cancer Centers of Nevada, Institut Paoli-Calmettes, Institut Curie, Aichi Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Eli Lilly (United States), Boehringer Ingelheim (Spain), Boehringer Ingelheim (Taiwan), Boehringer Ingelheim (China), University of Minnesota, Masonic Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3081636800

Cites:

Cited by:

Related to: 10